Roche Launches New Subcutaneous Immunotherapy For Lung Cancer Treatment

Pharma Major Roche has announced the launch of its subcutaneous formulation of the lung cancer immunotherapy drug Tecentriq in India, introducing a significant shift in cancer treatment delivery by reducing administration time from hours to just seven minutes. The new version, Tecentriq SC, allows the drug to be administered through a subcutaneous injection rather than the traditional intravenous infusion method. According to Roche, this innovation reduces treatment time by nearly 80%, bringing the delivery duration down to approximately seven minutes compared to the several hours typically required for IV-based immunotherapy sessions.

The company said the development is aimed at improving the overall treatment experience for cancer patients, many of whom require repeated cycles of immunotherapy over extended periods. Lung cancer remains one of the most common cancers in India, with an estimated 80,000 new cases diagnosed annually, making advancements in treatment efficiency particularly significant for the healthcare system. Medical experts have noted that immunotherapy has already transformed cancer care by improving outcomes in several cases, and the introduction of a subcutaneous option further enhances patient convenience.

Doctors point out that intravenous infusions often require extended hospital stays and can be physically taxing for patients, particularly those who are weak or undergoing multiple treatment cycles. Specialists also highlighted practical benefits of the new delivery method, noting that subcutaneous administration reduces the need for complex infusion setups and makes it easier for trained healthcare workers to deliver treatment in smaller or more accessible medical facilities.

Also Read: Delhi Govt Announces WFH For Two Days, Limits Foreign Travel For Officials

This is expected to improve patient compliance and reduce logistical challenges associated with hospital-based infusions. However, the convenience comes at a high cost. The maximum retail price of a single vial of the drug is around ₹3.7 lakh, and patients typically require multiple cycles depending on their stage of diagnosis and response to treatment. Doctors caution that overall treatment costs may vary significantly based on individual medical conditions and therapy duration.

The subcutaneous formulation has already been introduced in several Western markets in recent months, and its arrival in India marks an expansion of advanced oncology care options in the country. Experts say that while affordability remains a challenge, the innovation represents a meaningful step toward making cancer treatment more patient-friendly and accessible in terms of administration.

Also Read: Election Commission Announces SIR Phase 3 In Multiple States And UTs